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Abstract: The aim of this study was to assess the impact of laparoscopic gastric banding and laparoscopic sleeve
gastrectomy on the concentration of ghrelin, insulin, glucose, triglycerides, total and HDL-cholesterol, as well
as AST and ALT levels in plasma in patients with obesity. The research includes 200 patients operated using
LAGB (34 men average age 37.0 ± 12.6 years and 66 women average age 39.18 ± 12.17 years) and LSG (48 men
average age 47.93 ± 9.24 years and 52 women, 19 ± 9.33 years). The percentage of effective weight loss, effec-
tive BMI loss, concentration of ghrelin, insulin, glucose, triglycerides, total cholesterol, HDL-cholesterol,
LDL-cholesterol, ALT, AST and HOMA IR values was taken preoperatively and at 7th day, 1 month, 3 and 6 months
after surgery. Both after LSG and after LAGB, statistically significant reduction in BMI, serum insulin, glucose
and HOMA IR was noticed in comparison to the preoperative values. Post LAGB, patients showed an increase
of ghrelin, while LSG proved ghrelin decreased. Correlations between glucose and BMI loss, and between
insulin and BMI loss in both cases are more favorable in the LSG group. Lipid parameters, AST and ALT have
undergone declines or increases in the particular time points. Both techniques cause weight loss and this way
lead to changes in the concentration of ghrelin, as well as to the improvement of insulin, glucose, cholesterol and
triglycerides metabolism. They reduce metabolic syndrome and multiple comorbidities of obesity. (Folia His-
tochemica et Cytobiologica 2012, Vol. 50, No. 2, 292–303)
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Introduction
Obesity is an effect of a chronic imbalance between
energy supply and its expenditure according to envi-
ronmental, genetic or hormonal conditions. It is man-
ifested by the excessive gathering of adipose tissue
and leads to many serious coexisting diseases [1, 2].
As a global disease, obesity represents a serious
health, psychosocial and socio-economic problem
worldwide. The growing proportion of people with
excessive body weight results in a higher predisposi-
tion to develop the diseases associated with obesity
such as hypertension (HT), type 2 diabetes mellitus
(T2DM), cardiovascular diseases (CVD), dyslipi-
demia, sleep apnea, osteoarthritis, steatosis, depres-
sive disorders, and gastrointestinal cancers [1, 2].
WHO in 1997 put obesity on the list of social dis-
eases, which have come to embrace an increasing
number of areas of the world, especially over the past
two decades [3–5]. In 2005, the population of adults
(> 15 years old) with overweight was estimated at 1.6
billion, and those with obesity at 400 million. In Po-
land, it was noted that 1% of the population (over
300,000 people) had BMI > 40 kg/m2, while in urban
populations it was 2.8%, and in big cities 3% [6, 7].
Orexigenic and anorexigenic hormones play im-
portant roles in the regulation of energy balance, for
example ghrelin, isolated for the first time by Kojima
et al. in 1999 [8]. This is a 28-amino acid peptide re-
leased from X/A cells belonging to the system of scat-
tered endocrine cells of the APUD series. The high-
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est expression of ghrelin is observed in the stomach
fundus and it gradually reduces from the body of the
stomach to the colon [9]. Gastrectomy reduces ghre-
lin concentration in plasma by about 60%. What is
more, ghrelin is synthesized in the pancreas, kidney,
hypothalamus, placenta, pituitary and thyroid gland
[10]. The regulation of ghrelin secretion has yet to be
completely understood. However, it is known that its
concentration in plasma reduces in patients with
a positive energy balance, for example with obesity,
while in anorexia it  increases [11]. Moreover, certain
hormones and nutrients affect ghrelin secretion, and
ghrelin itself increases secretion of lactotropic and
corticotropic hormones. It influences the endocrine
part of the pancreas, inhibits insulin secretion [12]
and thus affects the metabolism of glucose. Like lep-
tin, ghrelin acts in an ‘informant’ role for the energy
balance of the central nervous system [13, 14].
Metabolic syndrome is a collection of risk factors
responsible for developing CVD and T2DM [15].
WHO determined that metabolic syndrome consists
of metabolic disorders such as insulin resistance rep-
resented by one of the following: T2DM, impaired
fasting glucose, impaired glucose tolerance or, in sub-
jects with normal fasting glucose (< 110 mg/dl), glu-
cose uptake below the lowest quartile for the back-
ground population in hyperinsulinomic and euglyce-
mic conditions. One of the following additional crite-
ria should also occur: antihypertensive medication
and/or high RR (systolic ≥ 140 mm Hg or diastolic ≥
≥ 90 mm Hg), plasma triglycerides ≥ 50 mg/dL, HDL
cholesterol < 35 mg/dl in men or < 39 mg/dl in wom-
en, BMI > 30 kg/m2 and/or waist hip ratio > 0.9 in
men or > 0.85 in women, albuminuria ≥ 20 mg/min
or albumin rate: creatinine ≥ 30 mg/g [16]. The Amer-
ican Heart Association recommends the ATP III clas-
sification (Adult Treatment Panel III), which includes
the following factors: abdominal obesity (waist cir-
cumference > 102 cm in male patients and > 88 cm
in female patients), aterogenic dyslipidemia (triglyc-
erides ≥ 150 mg/dl), high blood pressure (≥ 130/
/≥ 85 mm Hg), insulin resistance ± glucose intoler-
ance (≥ 110 mg/dl), proinflammatory state and pro-
thrombotic state [17].
The surgical treatment of obesity, especially laparo-
scopic gastric banding (LAGB) and laparoscopic sleeve
gastrectomy (LSG), is gaining wider interest. Recently,
despite the fact that LSG was introduced later, it has
gained popularity not only as a first step in the treat-
ment of superobese patients or patients at high risk, but
mainly as an isolated and definitive operation [18].
LAGB was first described in 1994 [19] and since
then it has become more popular. LSG was first de-
scribed in 1988 as part of a duodenal switch [20], and
in 1993 as an isolated technique [21]. The number of
LSG procedures in Europe and in the USA/Canada
is increasing. In 2003–2008, a growth was observed
from 0.0% to 4.0% (in USA/Canada) and to 7.0% in
Europe. However, this popularity should be reviewed
in the light of further research. A different situation
pertains with LAGB — its applicability in Europe in
2003–2008 decreased from 63.7% to 43.2%, while in
the USA/Canada it increased from 9.0% to 44.0%
[22]. In Poland, LAGB has been performed since
1998, and LSG since 2005, and with each passing year,
the application of these methods increases [6].
A growing number of publications have attempt-
ed an objective comparison of the different techniques
from various points of view. Yet there are still few
available publications describing LAGB and LSG ac-
cording to the percentage of effective BMI loss
(%EBL), and even fewer studies comparing the bio-
chemical effects.
The aim of this study was to assess the impact of
LAGB and LSG on the concentration of ghrelin, in-
sulin, glucose, triglycerides, total and HDL choles-
terol, as well as AST and ALT levels in patients with
obesity. Moreover, our aim was to assess the impact
of body weight loss on the comorbidities of obesity.
Material and methods
Our center is a pioneer in bariatric surgery in north eastern
Poland. In this study, we examined 200 obese patients who
underwent LAGB (n = 100) and LSG (n = 100) between
2005 and 2009 with a six month follow-up. The group of
patients with a gastric band included 34 men (average age
37.0 ± 12.6 years) and 66 women (39.18 ± 12.17 years).
The group of patients after sleeve gastrectomy included 48
men, average age 47.93 ± 9.24 years and 52 women — 44.19 ±
± 9.33 years. Preoperative BMI in the LAGB group was
45.21 ± 3.96 kg/m2 (average body weight 125.72 ± 15.9 kg);
in the LSG group it was 52.15 ± 8.5 kg/m2 (151.2 ±
± 25.19 kg) (Table 1).
Among patients classified for LAGB, T2DM was found
in eight patients (8%), HT in 12 (12%) and sleep apnea in
five patients (5%). In the group of patients classified for
LSG, these disorders were found in, respectively, 39 (39%),
56 (56%) and 31 patients (31%) (Table 2). All patients
complied with the criteria for bariatric treatment. Patients
over 40 years old, and with T2DM, HT, CVD, after heart
attacks, chronic obstructive pulmonary disease, sleep ap-
nea, osteoarthritis and varicose veins, were qualified for
LSG. LAGB was applied more frequently in female pa-
tients under 40 years of age, who were medially five years
younger than the LSG group of patients. Men in this group
were medially ten years younger. We preoperatively per-
formed a number of tests, including abdominal ultrasound
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and gastroscopy, to eliminate possible upper gastro-intes-
tinal tract pathologies. Patients were consulted by an en-
docrinologist, a nutritionist, a psychologist and, for wom-
en, by a gynecologist. All procedures were performed lap-
aroscopically using five trocars.
LAGB was performed typically through pars flaccida (in
several cases with perigastric technique), reaching the pos-
terior wall of the stomach with dissector. Afterwards the
silicone ring was dragged and closed around the stomach
near the angle of His, a 25–40 ml pouch was formed, and
then it was combined with the subcutaneal port above the
left costal arch.
LSG began with stomach estimation and localization of
the crow’s foot. Using harmonic scalpel or LigaSure®, ma-
jor omentum was cut close to stomach wall and medially to
gastro-omental vessels. Omentum was cut up to the left di-
aphragm branch and down 4–6 cm before pylorus. The first
load separated the major curvature from the crow’s foot,
and the next separated it longitudinally from the body to
the angle of His. Potential bleeding from line was continu-
ously supplied with electrocoagulation or hemostatic suture.
The stomach was reduced to a narrow tube. Then the proof
test was performed. Finally, the drain to that region was
applied.  Patients after LAGB were usually hospitalized for
one day, and after LSG for 2–3 days. All were discharged
with the recommendation of a low energy, low sodium and
semi liquid diet for the first two weeks, with the continu-
ance of a low-fat and low carbohydrate diet, and of a con-
trol visit every month. All patients were examined preoper-
atively, and seven days, then one, three and six months af-
ter the surgery, fasting 10–12 hours, by taking a clot blood
sample, which was then centrifuged to obtain serum. Chang-
es in ghrelin, insulin, glucose, total cholesterol, LDL-cho-
lesterol, HDL-cholesterol, triglycerides, ALT, AST, urea and
uric acid were determined after the surgery, which could
serve as a criterion for proper technique selection in order
to achieve the most effective results in treating comorbidi-
ties. Ghrelin was determined using Ghrelin (Total) RIA KIT,
(Millipore, Billerica, MA, USA). As the objective criteria,
we considered %EWL, %EBL and HOMA-IR. HOMA IR
was calculated using the formula: HOMA-IR = {[fast insu-
lin [mU/mL] × fast glucose [mmol/l]} / 22.5 [23]. Percent-
age of effective weight loss (%EWL) and %EBL were cal-
culated according to the guidelines from 2007 [24].
Statistical analysis was performed using Statistica 6.0
software for Windows. All values were given as mean ± SD.
The Mann–Whitney test was used for examining the differ-
ences between preoperative and postoperative values.
A value of p < 0.05 was considered to be significant [25].
Results
Having reviewed the material, it was found that a sta-
tistically significant reduction of BMI in patients un-
dergoing LAGB began seven days after the opera-
tion (41.74 ± 3.83 kg/m2) compared to the preopera-
tive values (45.21 ± 3.96 kg/m2). Similar observations
concerned one, three and six months after the sur-
gery (respectively 39.23 ± 3.91 kg/m2, 35.59 ± 4.11
kg/m2, 31.26 ± 5.31 kg/m2).
Table 1. Baseline characteristics of obese patients
LAGB (n = 100) LSG (n = 100)
Gender: female/male (%) 66/34 52/48
Age: female/male (y) 37.0 ± 12.6/39.18 ± 12.17 47.93 ± 9.24/44.19 ± 9.33
Weight [kg] 125.72 151.2 ± 25.19
BMI [kg/m˛] 45.21 ± 3.96 52.15 ± 8.5
Ghrelin [pg/Ml] 661.98 ± 180.5 491.49 ± 176.27
Insulin [µU/L] 22.71 ± 6.17 42.9 ± 28.82
Glucose [mg/Dl] 105.63 ± 28.87 147.7 ± 61.64
Total cholesterol [mg/dl] 207.37 ± 14.09 213.08 ± 19.68
Triglycerides [mg/dl] 127.25 ± 27.52 166.3 ± 51.64
LDL [mg/dl] 148 ± 20.02 138.44 ± 35.31
HDL [mg/dl] 44.7 ± 10.04 42.48 ± 11.19
ALT [UI/L] 29.57 ± 22.32 29.47 ± 11.52
AST [UI/L] 27.17 ± 16.5 25.5 ± 12.35
Uric acid [mg/dl] 4.97 ± 1.23 5.78 ± 1.73
Urea [mg/dl] 32.17 ± 13.57 32.22 ± 7.77
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During the six-month follow-up, %EWL and
%EBL was observed in both groups of patients. Sev-
en days after the surgery in the LSG group, we noted
a %EWL 13.57 ± 2.92%; after one month — 22.04 ±
± 3.95%; after three months — 32.5 ± 4.73%; and
after six months — 48.98 ± 6.58%. In the LAGB
group, the %EWL was higher than in the LSG group
seven days after the surgery (15.57 ± 4.9%), and re-
mained at the same level after one month (27.28 ±
± 7.38%); three months (44.03 ± 12.65%); and six
months (62.71 ± 21.17%). %EBL in the LSG group
after seven days reached 14.97 ± 3.45% — p irrele-
vant, after one month — 24.43 ± 5.09%; after three
months — 36.04 ± 6.48%; and after six months —
52.1 ± 7.28%. %EBL in different periods in the
LAGB group amounted to 17.75 ± 5.48%, p irrele-
vant seven days after the surgery, 29.6 ± 8.27% after
one month, 49.3 ± 14.3% after three months and 71.5 ±
± 22.82% after six months. %EWL and %EBL in-
creased after both bariatric procedures during the
whole of our follow-up (Figure 1).
Among all the analyzed parameters, the most
significant differences in both groups of patients
were observed in ghrelin. In the LSG group, we
observed a statistically significant reduction of gh-
relin seven days after the surgery (410.17 ± 91.56
pg/mL) compared to the preoperative period
(491.49 ± 176.27). Further observation showed
a statistically significant decrease of ghrelin after
one, three and six months (respectively 395.57 ±
± 58.76 pg/mL, 380.01 ± 60.78 pg/mL, and 389.08 ±
± 33.01 pg/mL). However, in patients after LAGB,
a statistically significant increase of ghrelin was ob-
served one month and three months after the sur-
gery (respectively 875.67 ± 83.47 pg/mL and 929.3 ±
± 172.49 pg/mL), compared to the preoperative pe-
riod (661.98 ± 180.5 pg/mL). In this group of LAGB
patients, a reduction after seven days (649.61 ±
± 205.76 pg/mL), and an increase after six months
(798.99 ± 153.92 pg/mL), were statistically insig-
nificant. Changes in concentration of ghrelin in in-
dividual follow-up are presented in Table 3.
During the entire six-month postoperative obser-
vation of patients after LAGB, statistically significant
changes in plasma insulin were observed, not only
seven days after the surgery (13.44 ± 3.84 µU/L) com-
pared to the preoperative value (22.71 ± 6.17 µU/L),
but also one month (12.38 ± 5.6 µU/L), three months
(9.52 ± 2.86 µU/L) and six months after surgery
(9.2 ± 0.54 µU/L). Analysis of changes in plasma in-
sulin proved the results to be statistically significant.
Seven days after the surgery, in patients after LAGB,
Table 3. Improvement of T2DM, hypertension and sleep apnea after LAGB and LSG in a six-month follow-up
LAGB LSG
Prior to surgery 6 months Prior to surgery 6 months
n % n % n % n %
Type 2 diabetes 8 8 4 50 39 39 21 53.84
Hypertension 12 12 7 58.33 56 56 26 46.28
Sleep apnea 5 5 3 60 31 31 16 51.61
Figure 1. Comparison of %EWL (A) and %EBL (B) after seven days, one, three and six months in patients after LAGB
and LSG. (*p < 0.01; **p < 0.05; ***p < 0.001; **** p < 0.00001)
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insulin levels had halved (21.4 ± 18.86 µU/L) com-
pared to the values before the surgery (42.9 ± 28.82
µU/L). Further measurements of the insulin in this
group of respondents showed further decreases one
month (19.31 ± 16.24 µU/L), three months (16.69 ±
± 13.55 µU/L) and six months after surgery (16.01 ±
± 8.41 µU/L) (Table 3).
All results of glucose in the LSG group were sta-
tistically significant compared to preoperative levels
(147.7 ± 61.64 mg/dL). Seven days after the surgery,
a decrease (112.79 ± 26.56 mg/dL) was observed,
which also occurred after one month (103.87 ± 12.06
mg/dL), three months (101.53 ± 10.5 mg/dL) and six
months after the operation (98.42 ± 7.8 mg/dL). In
contrast to the LSG group, examined glucose values
in patients after LAGB were statistically insignificant.
After the analysis of all glucose data, we noticed that
preoperative value (105.63 ± 28.87 mg/dL) had re-
duced seven days after surgery (92.43 ± 10.84 mg/dL).
After one month (96.25 ± 5.5 mg/dL) and three
months (96.75 ± 6.18 mg/dL) we observed an in-
crease, and finally, after six months, a statistically sig-
nificant reduction (93.5 ± 1.7 mg/dL).
Correlations between glucose and BMI loss (Fig-
ure 2A), and between insulin and BMI loss (Figure
2B) are both more favorable for LSG. Our study
proved that HOMA IR rate was statistically signifi-
cant in patients treated with the LSG technique, where
we noticed the increase to 5.11 ± 4.09 seven days af-
ter the surgery, compared to the preoperative value
(12.22 ± 13.4) and after one month to 4.02 ± 3.2.
After three months, the parameter increased to 4.22 ±
± 3.48, but after six months it reduced to 3.52 ± 2.52.
In patients after LAGB, the preoperative rate of
HOMA IR (6.83 ± 6.12) decreased seven days after
the surgery (3.83 ± 2.12) and after one month (3.4 ±
± 1.94). After three months, this level was maintained
(3.41 ± 2.09) but it increased after six months (3.87 ±
± 1.74). All these results were statistically insignifi-
cant in the LAGB group.
The results of total cholesterol were different. In
patients after LAGB, compared to preoperative val-
ues (207.37 ± 14.09 mg/dL), cholesterol level decreased
seven days after the surgery (187 ± 20.39 mg/dL)
and after one month (179.75 ± 11.2 mg/dL). Both
results were statistically insignificant. However, the
decrease after three months (173.25 ± 4.6 mg/dL)
and a slight increase after six months (178.6 ± 8.32
mg/dL) were statistically significant. In the LSG
group, the preoperative value (213.08 ± 19.68 mg/
/dL) had slightly decreased seven days after the sur-
gery (206.14 ± 12.74 mg/dL) but increased after one
month (210.55 ± 28.95 mg/dL). The further two re-
sults were statistically significant: a decrease after
three months (185.6 ± 11.36 mg/dL), and a slight
decrease after six months (182.22 ± 9.28 mg/dL).
After examining changes in the concentration of trig-
lycerides in the LSG group, we observed a statistical-
ly significant decrease of its value after one month
(122.64 ± 28.54 mg/dL), three months (118.43 ± 20.46
mg/dL) and six months after the surgery (116.45 ±
± 36.01 mg/dL), compared to preoperative values
(166.3 ± 51.64 mg/dL). The decrease of triglyceride
values seven days after surgery (151.57 ± 22.36 mg/dL)
was statistically insignificant. However, in the LAGB
group, preoperative levels of triglycerides (127.25 ±
± 27.52 mg/dL) significantly decreased after three
months (94.4 ± 13.68 mg/dL) and after six months
(81.5 ± 13.62 mg/dL). The lowering of concentration
after seven days (109.84 ± 15.54 mg/dL) and after
one month (105.67 ± 13.44 mg/dL) was statistically
insignificant.
All the results of HDL cholesterol from the LAGB
and LSG groups were statistically insignificant. In the
Figure 2. Correlation of BMI/plasma glucose (A) and BMI/plasma insulin (B) in patients after LAGB and LSG
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LAGB group, compared to the preoperative value
(44.7 ± 10.04 mg/dL), we found a significant reduc-
tion after seven days (31.45 ± 14.73 mg/dL). Subse-
quently, we observed an increase after one month
(35.1 ± 5.14 mg/dL) and after three months (38.6 ±
± 6.05 mg/dL), and a decrease after six months (37.07 ±
± 9.95 mg/dL). In the group of patients after LSG,
preoperative levels of HDL (42.48 ± 11.19 mg/dL) had
also significantly decreased after seven days (28.85 ±
± 5.97 mg/dL). However, further observations showed
an increase after one month (36.47 ± 10.62 mg/dL),
three months (39.88 ± 9.15 mg/dL) and six months
(43.8 ± 8.77 mg/dL).
After comparing preoperative values of another
fraction of cholesterol, LDL cholesterol, in the LAGB
group (148 ± 20.02 mg/dL), we noticed a decrease
after seven days (132 ± 33.85 mg/dL), and an increase
after one month (134.75 ± 9.63 mg/dL). The results
were statistically insignificant. However, after three
months (125 ± 10.96 mg/dL), and after six months
(124.57 ± 2.89 mg/dL), the observed declines were
found to be statistically significant. Further changes
were statistically significant both after three months
(110.51 ± 22.37 mg/dL) and after six months (111.78 ±
± 9.12 mg/dL). All measurements of ALT, in both
groups of patients, were statistically insignificant.
In patients after LAGB, ALT increased seven days
after the surgery (31.57 ± 17.38 IU/L) compared to
the preoperative value (29.57 ± 22.32 IU/L). We ob-
served a decrease after one month (22 ± 13.59 IU/L)
and after three months (19.25 ± 12.09 IU/L). After
six months, we noticed a slight increase (23 ± 11.28
IU/L), but it did not reach initial values. In the group
of patients after LSG, after seven days an increase
occurred (35.78 ± 12.22 IU/L) compared to preop-
erative values (29.47 ± 11.52 IU/L). In the further
follow-up, we observed declines (29.71 ± 11.29 IU/L)
after three months (24.1 ± 9.68 IU/L) and after six
months (23.23 ± 11.16 IU/L). AST in patients after
LAGB seven days after the surgery was higher (31.5 ±
± 19.98) than the preoperative value (27.17 ± 16.5
IU/L). After one month, we noticed a decrease (18 ±
± 7.1 IU/L), which occurred also after three months
(15.75 ± 7.1 IU/L). After six months, as in the case of
ALT, we observed an increase (17.83 ± 4.07 IU/L).
In the LSG group, seven days after the surgery we
recorded a higher (31.38 ± 11.51 IU/L) value than
the preoperative value (25.5 ± 12.35 IU/L). A de-
crease was observed after one month (24.8 ± 9.78
IU/L) and three months (19.35 ± 6.5 IU/L), but after
six months we noticed a growth (22.1 ± 11.16 IU/L).
Afterwards, we observed a decrease after one month
(24.8 ± 9.78 IU/L) and after three months (19.35 ±
± 6.5 IU/L), but an increase after six months
(22.1 ± 11.16 IU/L). All measurements of AST were
statistically insignificant in both groups.
Among the eight patients with T2DM from the
LAGB group, an improvement was observed after six
months in four patients, which is 50% of the diabet-
ics in the preoperative group. In the LAGB group,
hypertension improved in seven patients (58.33%) out
of 12 diagnosed preoperatively. Sleep apnea improved
in three patients (60%) from five diagnosed preoper-
atively.  Diabetes, diagnosed preoperatively in 39 pa-
tients in the LSG group, improved in 21 patients
(53.84%). From the group of 56 patients treated for
hypertension, after six months an improvement after
LSG was observed in 26 patients (46.28%). At the
same time, from the group of 31 patients who before
LSG complained of sleep apnea, in 16 (51.61%)
a reduction of symptoms was observed. The results
of the improvement of comorbidities in our patients
are presented in Table 3.
Discussion
The occurrence of obesity is increasing alarmingly
orldwide and is reaching epidemic proportions both
in developed and developing countries. Treatment
limiting the problem of obesity is an important re-
sponse to this health, psychosocial and socio-econom-
ic challenge. Diseases associated with obesity such as
HT, T2DM, CVD, dyslipidemia, sleep apnea syn-
drome, steatosis, gastro-esophageal reflux, peripher-
al edema, depression, depressive disorders, osteoar-
thritis and cancers are spreading [26, 27]. Eating habits
are of major significance in obesity statistics, and they
are closely related to the standard of living and eco-
nomic status. The highest percentages of obese peo-
ple are observed in the USA and Western Europe,
which most publications respond to. However, recent
results indicate a growing number of obese people in
developing countries, or in those recently regarded
as economically underdeveloped [5]. Poland is wit-
nessing intense progress in bariatric surgery. This is
connected with the increasing rate of obesity due to
changing lifestyle and eating habits. It appears we are
a part of a worldwide trend [6, 7].
Most publications have looked at bariatric proce-
dures from one particular point of view. In our study,
we tried to take into consideration a lot of metabolic
effects. It is valuable to observe changes not only in
one parameter, but also in the correlations of param-
eter groups. Therefore, in our study we present not
only changes in ghrelin, but also in insulin, glucose
and parameters of metabolic syndrome, in order to
determine which bariatric technique leads to better
results in reducing the effects of obesity. There have
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been only a few articles published to date that have
compared LAGB and LSG. We assumed that param-
eters of metabolic syndrome will decrease along with
the reduction of body mass. We tried to determine
whether there is any regular dependence of these pa-
rameters upon weight loss. We also asked the question
of whether ghrelin — which according to the literature
has a different concentration after each bariatric tech-
nique and which is produced outside the stomach, has
an influence on weight loss, i.e. whether the cells out-
side the stomach compensate for the loss in ghrelin-
producing cells after stomach resection. It has to be
established whether such resection of fundus is ef-
fective or whether a nonresective reduction of gastric
volume is enough [28, 29].
All bariatric procedures lead to a loss of body mass
[30]. This applies to LAGB and LSG which have sim-
ilar short-term results in terms of EWL, approximately
50–65%. The long term results of LAGB are less pos-
itive than those obtained after LSG, although the data
after LSG is still poor [29, 31]. Our results of weight
loss do not differ from the results of other bariatric
centers. We observed a decrease of %EWL and
%EBL which was maintained throughout the whole
six-month follow-up. From this perspective, our re-
sults in the LSG group are similar to Armstrong and
Malley’s [32] as well as Karamanakos’ [33] and in the
LAGB group to Ponce’s [34] and Jong’s results [35].
Short-term observations of global studies indicate that
the efficiency of both techniques is varied. In our fol-
low-up, we obtained more favorable results in the
LAGB group. Longer observations (> 1 year) indi-
cate that further weight loss is more beneficial in the
LSG group than in the LAGB group. It occurs after
one or two or three years or even longer, but the larg-
est effect can be observed one year and two years af-
ter the surgery [36–39].
LSG inhibits the production of ghrelin in 90% of
cases, while LAGB only does so in 1% [40]. Age and
sex do not influence the activity of ghrelin. Food in-
take plays the key role. Schindler et al. showed an
increase in ghrelin level after LAGB simultaneous
reduction of appetite, which is rather the result of
changes in eating habits than changes in peripheral
ghrelin concentrations [41]. Ghrelin concentration
decreases more steeply after a meal rich in carbohy-
drates than one rich in fats. The effects of a high-
protein meal as described in the literature often con-
tradict each other in different sources [13, 42].
It has been found that despite the reduction of
ghrelin levels, patients continue to lose body weight.
This suggests that the relationship between ghrelin
levels and weight loss is highly complex. Medical data
leads to a consensus that an increase of ghrelin levels
is induced by nonsurgical methods, such as low-calo-
rie diet, lifestyle modification, regular physical activ-
ity, anorexic, or cardiac, cancer and liver cachexias.
On the other hand, different bariatric procedures in-
fluence ghrelin levels differently. These discrepancies
can be explained by different ways of dealing with the
fundus in each bariatric procedure [43].
Comparing patients from both groups, we ob-
served a significant difference in the average concen-
tration of the only known peripheral orexigenic hor-
mone. Here, it has to be noted that in respect to age
we qualified older patients more usually to LSG than
to LAGB [44], and according to gender, we qualified
women to LAGB more usually than men. Women be-
fore LAGB were medially five years younger than the
group before LSG, and men were medially ten years
younger. Could this explain the differences in con-
centrations of ghrelin in different techniques?
Seven days after surgery, in both the LSG and the
LAGB group, a reduction in plasma ghrelin was ob-
served. In the LSG group, a decreasing tendency af-
ter one and three months maintained, but after six
months a slight increase was noted, similar to the lev-
el after one month. We noticed a completely differ-
ent course of changes in the LAGB group. After one
month, a significant increase was noticed, and after
three months the increase was maintained, although
it was lower. After six months, it had started to re-
duce. It was significantly higher than preoperative
values. In our follow-up, ghrelin levels differed slightly
from the results obtained at other centers. A com-
parison of ghrelin levels by Langer et al. in patients
who underwent LAGB and LSG has shown that the
LSG evoked a significant decrease in ghrelin on the
first day after surgery. Low levels were stable after
one month and six months, while after the LAGB,
after one month and after six months, an increase oc-
curred. After the LSG, reduction of ghrelin was sig-
nificant and permanent, as it was not after the LAGB.
In addition, LSG resulted in a more significant de-
crease in body weight loss after one and after six
months than LAGB [45]. Bohdjalian et al. [46] de-
scribed declined ghrelin values after one, three and
six months, and they noticed that those values were
stable one year or even five years later, in terms of
both total and acylated ghrelin.
Based on these results, some scientists have pos-
tulated that LSG should be the first choice in the treat-
ment of superobesity [47, 48]. Based on our own ex-
perience and on the results from other centers, we
can assume that the reduction in ghrelin levels may
influence weight loss, but it is not the only factor which
can determine the effectiveness of LSG in the treat-
ment of obesity [49].
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The test results are not fully explained when the
interaction between ghrelin and insulin is taken into
consideration. Saad et al. pointed out that insulin is
a physiological and dynamic modulator of plasma
ghrelin, and insulinemia mediates between nutrition
status and energy balance and ghrelin levels in plas-
ma [50]. Another study has confirmed that in obese
patients, insulinemia and insulin are inversely asso-
ciated with low ghrelin levels in plasma, and thus
may have a feedback loop in the regulation of body
weight [51].
Bariatric procedures causing loss of body weight
improve glucose metabolism and reduce insulin re-
sistance, which explains the results in remission of
T2DM. In regard to the unquestionable impact of
bariatric procedures on the T2DM [52], in which hy-
perinsulinemia is closely associated with insulin re-
sistance [53], the LAGB is ambiguous. However, LSG
provides tangible benefits, although in this case, we
only studied the medium-term research. Moreover,
Silecchia et al. documented resolution of insulin non-
dependent diabetes in 69.2%/76.9% and improvement
in 15.4%/15.4% after 12/18 months in superobese pa-
tients after LSG [54]. In a retrospective study of
30 patients after LSG, DM resolution in 27% of pa-
tients was observed after two months and in 63% af-
ter six months. Patients with T2DM lasting < 5 years
experienced more favorable results after bariatric
treatment [55]. Rizzello et al. showed a rapid improve-
ment of insulin, including insulin resistance after LSG
not connected with EWL [56].
The relationship between insulin resistance and
obesity has been examined and documented. Buch-
wald’s meta-analysis found resolution in 78% and
resolution/improvement in 87% of patients with
T2DM after bariatric procedures. For example, in the
LAGB group, over 50% of patients experienced
a resolution. In terms of benefits in the resolution of
T2DM and weight loss, LAGB is less effective than
gastric bypass. This leads us to suppose that LSG
would be found between these two, and would lead
to more beneficial effects on diabetes than LAGB
[57]. In a study comparing LAGB and LSG, Frezza
et al. found that LSG provides a greater weight loss
and better control of glucose at 12 and 18 months
than LAGB, suggesting that resection of the stomach
fundus plays an important, though as yet not com-
pletely explained, role [29].
Another comparison of both surgical techniques
led to a statistically significant finding that in the LSG
group resolution or remission of T2DM, HT and hy-
perlipidemia improved [58]. We also noticed that af-
ter LAGB and LSG, and having weight loss deter-
mined, there was an improvement in symptoms of
metabolic syndrome components, but the effect was
stronger after LSG. This results in reduction of the
demand for previously used medications. Parikh et
al. examined the effect of LAGB on %EWL in dia-
betics and the use of oral hypoglycemics in the post-
operative period. They observed that after one year,
%EWL decreased by 43%, and after two years by
50%, and that after one year 39% of the patients in
this group required oral hypoglycemics, and after two
years — 34%. After one year, 14% of patients re-
quired insulin, and after two years — 18% [59].
Furthermore, LSG and LAGB are comparable
when T2DM and the metabolic syndrome remission
after one year of observation are taken into consider-
ation [60, 61]. Peterli et al. observed the reduction of
plasma insulin and glucose levels seven days and three
months after LSG, which was similar to the results
after LGBP. Therefore, the authors suggest that the
small intestine does not mediate significantly in im-
proving glucose homeostasis [62].
On the other hand, Lee et al. compared the change
in insulin resistance in patients after one, three and
six months and 1one, two and three years after LAGB
and LGBP. They found that both techniques led to
lower insulin resistance, without a clear effect of ex-
clusion of the duodenum and small intestine [63]. In
their opinion, the improvement was related to weight
loss, and not to the chosen surgical technique. An-
other comparison of patients after LAGB and LGBP
shows significant impact of %EWL on improving in-
sulin resistance after one year in both cases [64].
During our research, we found significant differ-
ences in insulin and glucose concentrations between
groups of patients after LAGB and LSG. In both
groups, we observed a statistically significant reduc-
tion in insulin. The most significant decrease occurred
seven days and three months after the surgery. In both
cases, we noted a decrease in glucose levels after sev-
en days, while the effect was more visible and statisti-
cally significant in the LSG group. Glycemia after LSG
decreased after a month, while in the LAGB group
we noticed a slight increase in blood glucose com-
pared to the measurement after seven days, which
continued to increase after three months but de-
creased after six months. Insulin resistance expressed
by HOMA IR among our patients showed more no-
ticeable reduction seven days and one month after
the surgery in the LSG group than in the LAGB group.
Moreover, changes after six months in both groups
were insignificant, but in the LAGB group a slight
increase occurred, and in the LSG group a slight de-
crease.
As research indicates, in patients with second and
third degree obesity, metabolic surgery has surpris-
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ingly positive results in the reversibility of the conse-
quences of metabolic syndrome, mainly through
weight loss. But we also need to include preoperative
levels of TG and diabetic status [65]. Although only
a few publications have examined the effects of dif-
ferent surgical techniques on metabolic syndrome, we
know already that both LAGB [66] and LSG [54] con-
tribute to a noticeable improvement of the other com-
ponents of metabolic syndrome, such as triglycerides,
cholesterol and its fractions. In the case of LSG, long-
-term studies show that weight loss does not always
improve lipid parameters [67]. As already stated, LSG
has a similar effect on the metabolic syndrome as
LGBP [68]. However, other studies have  claimed that
LGBP improves metabolic syndrome more signifi-
cantly than LSG [69]. In our material, reduction of
triglyceridemia was visible after seven days, but the
highest decrease was observed after one month, and
later it decreased much less rapidly. In addition, total
cholesterol was reduced in both groups after six
months. In both cases, within six months a gradual
reduction of triglyceridemia occurred. In LAGB,
a less significant decrease occurred after one month,
while at the same time the decline was the highest
after LSG. HDL after six months was characterized
by similar changes in both cases, although it was more
clearly visible after the LSG, especially after seven days
and one month. The most significant change was no-
ticeable after six months, when after LSG, HDL-cho-
lesterol continued to increase, but decreased slightly
after LAGB. Changes in LDL-cholesterol also were
more visible after the LSG, especially after one and
three months. The preoperative values of ALT were
equal after LAGB and LSG. After seven days, one
month and three months, those values significantly dif-
fered from each other, but after six months they were
the same again. On the seventh postoperative day, ALT
and AST values increased, which we believe was a re-
sult of the surgery.
Chen et al., in their study, attempted to demonstrate
that there is a synergistic relationship between obesity,
insulin resistance and ALAT. They suggest that such
coexistence can be more clinically valuable in diagnos-
ing insulin resistance than the metabolic syndrome [70].
Bariatric surgery has become the treatment of
choice for morbid obesity and as the only one proven
in the long-term control of weight loss. Moreover, the
majority of patients with comorbidities have reached
a complete recovery or improvement. It has  also been
noticed that in patients with a higher number of co-
morbidities, the impact of bariatric surgery was greater
[71]. The weight loss after LSG is achieved in a re-
strictive way and by hormonal modulation. Restric-
tion plays the most important role after LAGB. In
our center, LAGB and LSG are currently the two most
commonly applied bariatric techniques [72].
Examining the history of bariatric surgery, the
constant development of technology and standards
of treatment can be observed. It can be stated that
this evolution leads to the reduction of the risk of
postoperative complications and patient discomfort,
which also considerably influence the effects of treat-
ment. The application of SG as a sole and definitive
treatment can be regarded as a significant develop-
ment. Gastric resection was so for an integral part of
one-step procedure [47].
Not only in terms of the potential metabolic ben-
efits must an important remark be made regarding
the recently described combination of sleeve gastrec-
tomy and gastric banding as an initial treatment [73].
It would be useful to consider the effects of connec-
tion of restrictive and malabsorptive techniques. It
seems that this method may have a justification, since
the band protects against stretching the stomach, and
resection of the gastric fundus with the ghrelin-pro-
ducing cells reduces hunger. However, these argu-
ments require clinical revision.
One of the first publications discussing glucose
homeostasis and weight loss in patients undergoing
the sleeve + banding technique [74] was recently re-
leased. The developments it describes are promising,
but due to the small number of patients and the short
follow-up, they require further observation.
Conclusions
Both surgical techniques lead to weight loss, although
in long-term follow-up, %EBL increases more effec-
tively after LAGB.
According to our observations, and the opinions
of other authors, we conclude that the improvement
of metabolic parameters is a result of weight loss, and
not a consequence of bariatric procedure. Ghrelin
level after LSG is reduced due to the resection of the
fundus and body of the stomach, which abates the
consumption of carbohydrates and fats.
Bariatric treatment has a directly beneficial im-
pact on patients’ health status by reducing the symp-
toms of comorbidities such as T2DM, HT and sleep
apnea. Both techniques contribute to the improve-
ment or resolution of T2DM by reducing insulin re-
sistance and glucose metabolism.
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